Terumo Stock (OTC:TRUMY), Trade Ideas

Terumo

Terumo Corp manufactures and sells medical products and equipment. The firm has three main businesses: blood management, cardiac and vascular, and general hospital. The cardiac and vascular business generates the largest proportion of revenue and sells cardiac and endovascular interventional therapies, cardiovascular surgical systems, neurovascular products, and vascular graft products. The general hospital business includes diabetes management, consumer healthcare, drug and device technologies, and general hospital products. The blood management business sells blood component, therapeutic apheresis, and cellular technologies. Terumo generates the majority of its revenue in Asia, with Japan contributing the largest proportion of Asian revenue.

NARI

Analyst Color

Equities

News

Health Care

Price Target

Initiation

Analyst Ratings

Trading Ideas

General

TRUMF

TRUMY

Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.

Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst

Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?

Biotech

Penny Stocks

STSS

The medical device and supply manufacturing industry is focused on the design and production of medical instruments and devices.

With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO

Medical device company Sharps Technology Inc. (NASDAQ: STSS) is taking stock as it approaches one year since its initial public offering (IPO). Since its IPO, the company has taken major strides in manufacturing and marketing, and is rolling out the first of its innovative  syringe products. 

Terumo Corp

Terumo Corporation (TRUMF) Q1 2024 Earnings Call Transcript

Terumo Corporation 2024 Q1 - Results - Earnings Call Presentation

Terumo Modestly Undervalued, But Not Really Exciting

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Terumo Corporation (TRUMF) Q2 2024 Earnings Call Transcript

Improved Revenue Growth Is Terumo's Next Major Target

Terumo Corporation 2023 Q3 - Results - Earnings Call Presentation

Terumo Corporation (TRUMF) Q3 2024 Earnings Call Transcript

A rating of 82 puts Terumo ADR (TRUMY) near the top of the Medical Instruments and Supplies industry according to InvestorsObserver. Terumo ADR's score of 82 means it scores higher than 82% of stocks in the industry. Terumo ADR also received an overall rating of 58, putting it above 58% of all stocks. Medical Instruments a

Where Does Terumo ADR (TRUMY) Stock Fall in the Medical Instruments & Supplies Field After It Has Risen 7.37% This Week?

AORT

CSLLY

Small Cap

Press Releases

IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium

Ventricular Assist Device Market Size, Growth, 2023-2031

Terumo Medical Corporation's New AZUR HydroPack™ Peripheral Coil System Provides a Soft-Packing, Long-Lasting Solution to Embolotherapy

ICCM

TYO:4543